Paper Details

  1. Home
  2. Paper Details

A comparative study of the effects of carbamazepine and the NMDA receptor antagonist remacemide on road tracking and car-following performance in actual traffic.

Author: LamersJ, LewisM, LocktonA, MobbsE, MuntjewerffD, RamaekersG, SandersN, VerheyF

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Remacemide, an antiepileptic drug, does not affect driving performance. Carbamazepine, another antiepileptic drug, can impair driving performance, particularly during initiation therapy.
Paper Details　
Original Abstract of the Article :
RATIONALE: Antiepileptic drugs are known to produce side effects which may impair driving performance. Performance effects, however, may differ substantially between individual antiepileptic drugs. OBJECTIVE: To compare the effects of carbamazepine, remacemide, and placebo on actual driving perform...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s002130100898

データ提供：米国国立医学図書館（NLM）

Carbamazepine and Remacemide: Driving in the Desert of Epilepsy

Antiepileptic drugs are essential for managing epilepsy, but they can also affect driving performance. This study compared the effects of carbamazepine and remacemide, two antiepileptic drugs, on driving performance in real-world driving scenarios. Imagine two travelers navigating a desert road, one with a clear mind, the other slightly disoriented. This study aims to understand how these medications affect driving abilities.

Carbamazepine's Impact on Driving Performance

The study found that carbamazepine impaired driving performance, while remacemide did not. Carbamazepine was associated with decreased road tracking precision and slower reaction times. This suggests that carbamazepine may pose a risk for drivers, especially during the initial stages of treatment. It's like driving a vehicle with a slightly wobbly steering wheel in the desert, making navigation more challenging.

Driving Safely with Epilepsy

This study emphasizes the importance of careful consideration when driving with epilepsy. It's crucial to discuss medication side effects with your doctor and make informed decisions about driving. This is like choosing the right route in the desert, taking into account the terrain, weather, and your vehicle's capabilities.

Dr.Camel's Conclusion

This research highlights the importance of considering the potential impact of antiepileptic medications on driving performance. It's essential to work closely with your doctor to ensure your safety and make informed decisions about driving.

Date :
  1. Date Completed 2002-04-02
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

11862350

DOI: Digital Object Identifier

10.1007/s002130100898

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.